Pfizer (NYSE:PFE) has been assigned a $38.00 target price by equities researchers at Deutsche Bank in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank’s price target points to a potential upside of 6.65% from the stock’s previous close.

Other research analysts have also issued research reports about the company. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Saturday, November 25th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a report on Thursday, November 23rd. Jefferies Group set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $38.66.

Shares of Pfizer (NYSE PFE) opened at $35.63 on Wednesday. Pfizer has a twelve month low of $30.51 and a twelve month high of $36.78. The firm has a market capitalization of $214,943.11, a PE ratio of 14.42, a P/E/G ratio of 2.54 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the firm posted $0.61 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. analysts forecast that Pfizer will post 2.59 earnings per share for the current year.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 60,280 shares of company stock valued at $2,118,988 in the last 90 days. 0.06% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Lowe FS grew its stake in shares of Pfizer by 54.9% in the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock worth $23,000 after acquiring an additional 260 shares during the last quarter. Taylor Wealth Management Partners grew its stake in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 105 shares during the last quarter. Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer in the second quarter worth $102,000. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer in the second quarter worth $103,000. Institutional investors own 69.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Pfizer (PFE) Given a $38.00 Price Target by Deutsche Bank Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/06/pfizer-pfe-given-a-38-00-price-target-by-deutsche-bank-analysts.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.